For those following the proceeding between AbbVie and Jansen relating to Stelara, the Court docket indicates a settlement was reached and today the Court issued an order that all claims and counterclaims be dismissed with prejudice. In October, the Federal Court of Appeal had set aside the trial decision and ordered a new trial.

Some of the decisions on the proceeding, T-1310-09 (Stelara/Ustekinumab) were:

• 2013 FC 1148 – regarding amendments to the alleged prior art, later reversed on appeal in 2014 FCA 242
• 2014 FC 55 – trial decision, later set aside in 2014 FCA 242
• 2014 FC 489 – imposing a partial injunction, also set aside 2014 FCA 241
• 2014 FC 863 – a show cause decision for allegations of violations of the injunction

See my earlier post on this proceeding when the trial decision was issued in January 2014.